Charles Rosier’s Career Experiences
A leading investment bank that operates globally is GMS (Goldman Sachs). In his role as their Managing Director, he paid much attention to public asset management. As a partner at BTG Pactual Bank, he got the opportunity to work with a well-known institution with 30 years of experience, employing more than 2,500 workers in various locations in Latin America. Charles Rosier (http://dooid.me/charlesrosier) worked as the Debt Capital Manager at SBC Warburg from 1997 to 2009. He also worked at Lehman Brothers where he started his dream career as an investment banker.
In 1991, Charles Rosier completed his scientific degree at Fenelon Sainte-Marie. He didn’t settle for a single job but took other positions in the industry while an investment banker. Joining the BTG Pactual Bank, Charles Rosier worked with them until 2010.
In 1999, Goldman Sachs (GMS) offered Charles Rosier a new job opportunity. After taking the offer, he was appointed as their Managing Director. There are approximately 2,500 workers employed at BTG Pactual, which has 30 years of experience. He handled the French-speaking markets of France, Belgium and Quebec. Charles Rosier finally joined BTG Pactual in August 2010. He became partners with an investment bank in Latin America: BTG Pactual.
In 2012, Charles Rosier assisted a French performer toprofitably produce her debut album and did a lot for a Silver Lion-winning film, before its production and release in the year 2006. His splendid support for a well known French female performer was a great example of his passion for culture and music. He has always had a love for music and singing. He also loves to watch movies and that is why he admires French culture so much. Charles Rosier has a passion for culture and music. This shows in the way he supports movies and artists.
Healthcare Projects Charles Rosier Supported
Charles Rosier first started out a healthcare project as an investor at Mapreg, a pharmaceutical firm headed by Professor Etienne Baulieu. Baulieu and his co-workers found it challenging to develop a new drug due to lack of budget, which he addressed. He is also one of the investors of Mapreg, a medical laboratory in Paris that examines depression, strokes and other serious cases.